(Q38131166)

29 August 2017

Genetics and biomarkers in personalisation of lung cancer treatment (English)

1 reference

29 August 2017

0 references

1 reference

1

Rafael Rosell

1 reference

29 August 2017

2

Trever G Bivona

1 reference

29 August 2017

Niki Karachaliou

3

1 reference

PubMed ID

23972815

29 August 2017

language of work or name

English

0 references

publication date

1 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

382

1 reference

29 August 2017

720-731

1 reference

29 August 2017

9893

1 reference

Non-small-cell lung cancer.

29 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Cancer genome landscapes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

A missing link in genotype-directed cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

New driver mutations in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

SnapShot: non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

The transcriptional landscape and mutational profile of lung adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Genetic insight and therapeutic targets in squamous-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Lessons from the past: evolutionary impacts of mass extinctions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

EGFR mutations in circulating tumour DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Frontiers: PED/PEA-15, a multifunctional protein controlling cell survival and glucose metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Bim-targeted cancer therapy: a link between drug action and underlying molecular changes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Alterations of the Notch pathway in lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Selective requirement for Mediator MED23 in Ras-active lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

The hallmarks of cancer: a long non-coding RNA point of view.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

GLI activation by atypical protein kinase C ι/λ regulates the growth of basal cell carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

The crosstalk of mTOR/S6K1 and Hedgehog pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

TGFβ signalling in context

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Mediating resistance in oncogene-driven cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Detection of mutations in EGFR in circulating lung-cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'-monophosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Inhibition by cAMP of Ras-dependent activation of Raf.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Mechanisms of acquired resistance to ERK1/2 pathway inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Lessons from the cancer genome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961715-8

7 January 2021

10.1016/S0140-6736(13)61715-8

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ovu6k7f4yja6djbqpj7jet5aci

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_ovu6k7f4yja6djbqpj7jet5aci

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ovu6k7f4yja6djbqpj7jet5aci

30 July 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/ovu6k7f4yja6djbqpj7jet5aci

30 July 2022